This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Pardes Biosciences Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Pardes Biosciences.
Key information
36.6%
Earnings growth rate
39.3%
EPS growth rate
| Biotechs earnings growth | 27.3% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 17 Jul 2023 |
Recent future growth updates
Recent updates
We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate
Jul 18
Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation
Jan 20We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully
Oct 01Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19
Sep 13Pardes Biosciences GAAP EPS of -$0.48
Aug 15Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans
Jun 14Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform
Jan 21Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | N/A | -34 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -33 | N/A | N/A | 1 |
| 12/31/2023 | N/A | -77 | N/A | N/A | 1 |
| 6/30/2023 | N/A | -76 | -79 | -79 | N/A |
| 3/31/2023 | N/A | -93 | -78 | -78 | N/A |
| 12/31/2022 | N/A | -97 | -72 | -72 | N/A |
| 9/30/2022 | N/A | -87 | -76 | -76 | N/A |
| 6/30/2022 | N/A | -75 | -67 | -67 | N/A |
| 3/31/2022 | N/A | -55 | -54 | -54 | N/A |
| 12/31/2021 | N/A | -39 | -37 | -37 | N/A |
| 9/30/2021 | N/A | -36 | -23 | -23 | N/A |
| 6/30/2021 | N/A | -27 | -14 | -14 | N/A |
| 3/31/2021 | N/A | -20 | -8 | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRDS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PRDS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PRDS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if PRDS's revenue is forecast to grow faster than the US market.
High Growth Revenue: PRDS is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PRDS's Return on Equity is forecast to be high in 3 years time